Jazz Pharmaceuticals plc JAZZ revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Jazz Pharmaceuticals plc reported revenue across 17 products and services; the largest, Product And Services Product Sales Net Of Deductions, was $4.02B (+5.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product And Services Product Sales Net Of Deductions$4.02Bshare n/a+5.3% yoy
- Total Neuroscience$2.88Bshare n/a+6.7% yoy
- Xywav$1.66Bshare n/a+12.5% yoy
- Total Oncology$1.13Bshare n/a+1.6% yoy
- Epidiolex Epidyolex$1.06Bshare n/a+8.9% yoy
- Rylaze Enrylaze$403Mshare n/a-1.9% yoy
- Zepzelca$307Mshare n/a-4.1% yoy
- Product And Services Royalties And Contract Revenue$246Mshare n/a-0.8% yoy
- +9 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$3.83B89.8%+4.7% yoy
- Europe$341M8.0%+9.1% yoy
- Other countries$94.9M2.2%-1.3% yoy
Members sum to the consolidated $4.27B for this period.
- Product And Services Product Sales Net Of Deductions$1.03Bshare n/a+22.1% yoy
- Sleep$439Mshare n/a+15.0% yoy
- Xywav$408Mshare n/a+18.4% yoy
- Oncology$333Mshare n/a+45.3% yoy
- Epilepsy$250Mshare n/a+14.7% yoy
- Epidiolex Epidyolex$250Mshare n/a+14.7% yoy
- +11 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.